Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
(Posted: 04/12/2010) - Results from a large randomized clinical trial indicate that men at an increased risk for prostate cancer reduced their risk with regular use of the drug dutasteride (Avodart).
Internal Radiation Effectively Reduces Local Recurrence of Some Endometrial Cancers
(Posted: 03/31/2010) - Vaginal brachytherapy was as effective as external-beam radiation therapy at reducing the rate of cancer recurrence in the vagina and had fewer side effects for women with high-intermediate risk endometrial cancer, according to a study published March 6, 2010, in the The Lancet.
Drug Slows Progression of Cutaneous T-Cell Lymphoma
(Posted: 03/31/2010) - Patients with cutaneous T-cell lymphoma who received the drug denileukin diftitox survived without disease progression for a median of more than 2 years, compared with just over 4 months for patients who received a placebo, according to a study published March 8, 2010, in the Journal of Clinical Oncology.
Shorter Course of Radiation Effective and Safe for Some Women with Early-stage Breast Cancer
(Posted: 03/15/2010) - Giving radiation therapy in fewer but larger doses may be an alternative to standard radiation therapy for some women with early-stage breast cancer, according to a study published in the February 11, 2010, New England Journal of Medicine.
Trastuzumab Benefits Women with Locally Advanced or Inflammatory Breast Cancer
(Posted: 03/15/2010) - Women treated with trastuzumab (Herceptin) and chemotherapy before surgery and trastuzumab again after surgery had a reduced risk of the disease recurring or progressing compared with women who received pre-surgical chemotherapy but no trastuzumab, according to a study published in the January 30, 2010, Lancet.